PCM
BMY.RT

Pentwater Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Pentwater Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-69,050,000
Closed -$47.7M – 419
2020
Q4 		$47.7M Buy
69,050,000
+30,983,188
+81% +$66M 0.58% 29
2020
Q3 		$85.7M Sell
38,066,812
-15,478,000
-29% -$44.2M 1.11% 20
2020
Q2 		$192M Buy
53,544,812
+535,000
+1% +$1.93M 3.41% 8
2020
Q1 		$201M Buy
53,009,812
+17,456,000
+49% +$57.5M 3.33% 10
2019
Q4 		$107M Buy
+35,553,812
New +$92.5M 1.75% 14

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Pentwater Capital Management's BMY.RT Position: Q1 2021 in Review

Pentwater Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 69,050,000 shares — an estimated $47.7M sold.

Pentwater Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $201M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Pentwater Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 69,050,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $47.7M.
  • Pentwater Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Pentwater Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $201M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Pentwater Capital Management's 13F filing for Q1 2021, filed 17 May 2021.